AC-065B302 Select: Radomized double blind placebo controlled parallel group group sequential adaptive Phase 3 study with open label extention period to assess efficacy and safety of Selexipag
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Janssen Research & Development, LLC
Start Date
December 19, 2019
End Date
November 14, 2023
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Janssen Research & Development, LLC
Start Date
December 19, 2019
End Date
November 14, 2023